Chicago—Controversy over the use of ezetimibe/simvastatin to prevent progression of atherosclerosis continues to grow.
At the American Academy of Cardiology's 57th Annual Scientific Session here in March, attendees packed the lecture hall to hear a detailed account of the ENHANCE (Effect of Ezetimibe Plus Simvastatin vs Simvastatin Alone on Atherosclerosis in the Carotid Artery) trial, 2 months after the company released the study's major findings to the media rather than to the scientific community. After the presentation, a panel assembled by the academy to put the findings in perspective declared that the aggressively marketed drug combination should be used only as a last resort in treating patients to decrease their levels of low-density lipoprotein cholesterol (LDL-C).
Mitka M. Cholesterol Drug Controversy Continues. JAMA. 2008;299(19):2266. doi:10.1001/jama.299.19.2266
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: